Skip to main content
BIOA $5.22 -5.95%
BIOA logo
BIOA · BioAge Labs, Inc.
Track BIOA — free
$5.22 -0.33 (-5.95%) At close · Nov 16 Play latest call Q1 2026 earnings call transcript
Market Cap
$239.90M
Shares
45.96M
Volume · Nov 16 689.11K Avg daily vol (3M) 733.08K
All webcasts

Conference · 2026-11-10

BioAge Labs, Inc. (BIOA) November 10, 2026 Conference Transcript

Concluded Nov 10, 2026 Audio replay
Nov 10, 2026 25:04 41 turns
Period
2026-11-10
Runtime
25:04
Sources
2 artifacts

Transcript & audio

25:04 Audio
Seamus Fernandez Analyst — Guggenheim

All right, good morning, everybody. Thanks so much for joining us here at Guggenheim's Healthcare Innovation Conference. I'm Seamus Fernandez, one of the senior biotech analysts here at Guggenheim. Really pleased to be joined by BioAge. Immediately to my left is Kristen Fortney, co-founder and CEO. So, you know, Kristen, maybe just to sort of kick us off, let's start off with a high-level overview of BioAge's focus and, you know, how the platform and the pipeline, you know, really support BioAge's mission in particular.

Yeah, for sure. And thanks, Seamus, for having me here today. We're pleased to be here. Looking forward to the conference. But briefly, BioAge is focused on, we have a platform based on human data, and specifically longitudinal human aging data to find pathways and targets that are important for metabolic aging, you know, healthy lifespans. And it was that data that led us to NLRP3 as well as APJ, where we have programs running, as well as sort of preclinical collaborations and preclinical programs that we'll speak to, I think, later. But broadly right now, our lead product is BGE102. This is a potential best-in-class brain penetrant NLRP3 inhibitor currently in two Phase II clinical trials with data coming later this year, as well as in the second half of next year. This is a target with many different potential applications from cardiovascular to ocular to neuro, so we're really looking forward to those imminent readouts, and, you know, I'm sure we'll speak about all of that in greater depth, and then we're also really excited to be back in the clinic again soon with APJ, so we're on track to file IND by end of this year, and that's when we'll give our sort of clinical timing as well for this really exciting target that's relevant to obesity and muscle. Great.

Seamus Fernandez Analyst — Guggenheim

So, you know, just in terms of the picking the targets, the, you know, longevity approach is potentially useful in picking targets. Can you talk a little bit about the approach itself and the platform?

Yeah, for sure. So what's unique about our data, and this is partially inspired by, you know, data sets like UK Biobank or DecoGenetics that Amgen bought have been so useful, but they're not necessarily the best data sets for understanding aging because the length of the follow-up, like they often have longitudinal samples from people, but maybe one or two over 10 or 20 years, right? And what we wanted to do is we wanted to understand Disease before it starts, you know, right? Like you can look. There's a lot of diseases that happen to you when you're 80 that don't happen when you're 20. So something is very different about your body when you're 80 versus when you're 20. And so we wanted to create a data set that was like UK Biobank where the key difference was the length of the follow-up. And so we have thousands of samples from these great population data sets where we have 50 years of longitudinal samples, right? So that first sample is collected when someone is middle-aged and healthy. You have them sequentially profiled through time until their death. And you can go into that sample, measure, you know, all the proteins, all the metabolites using today's technologies, and correlate that to future outcomes. Like which, you know, what is different about those individuals who went on to live healthier and longer than the rest of us? What is different about those people who had, you know, improved physical function with aging or improved cognitive abilities, right? So those are the kinds of questions we ask at the data.

Seamus Fernandez Analyst — Guggenheim

Got it. And, you know, just in terms of partnerships that are ongoing, centered on the platform, just what are the goals of each partnership and, you know, any milestones that have been reached?

Yeah, so we have two pharma collaborations on our platform, on our human platform. The collaboration with Lilly is around a couple of targets that are novel that we think are exciting from our own data, and they're helping us build molecules. The collaboration with Novartis is a bigger one. And to be clear, right, those Lilly programs would be ones that we would bring inside. They would be part of our clinical pipeline eventually. And in contrast with Novartis, that's really like a big discovery collaboration. Novartis, like us, is really keen on human data as sort of de-risking for drug discovery. And on aging, too. They have a whole department of aging research under Fiona Marshall. And they really wanted to look with us about, you know, the intersection of, like, what is important for human aging and what's important about their response to exercise, right? Because a lot of these, you know, your ability to, you know, maintain muscle mass, things like that, declines as you get older, and that's related to aging biology but also exercise biology. So it's really a big, you know, integrative exercise to find novel targets. Like, they're explicitly interested in things where people haven't built programs before, and we're going to advance some of those. Some of those will be targets that BioAge works on, some of them will be targets that Novartis works on, and that was a deal that came with upfront milestones, FTEs. It's a great way to fund the expansion of our platform internally as well.

Seamus Fernandez Analyst — Guggenheim

So let's talk about NLRP3. You know, let's start first with what's unique about BGE 102.

Yeah. So, you know, this is a target that there's a few other programs out there. We initially got excited about it because of our human data, and specifically in our human data sets, having elevated NLRP3 predicted shorter lifespan, and specifically accelerated cognitive decline. So from the outset, we really wanted to build something that was brain penetrant. That was part of our design goal. And we also wanted to build something that was different from the original molecules, like MCC950 with Pfizer, et cetera. And we set out to, you know, we eventually discovered a novel binding site. So we have the only novel binding site to NLRP3 distinct from, you know, the same binding pockets that everybody else is working on. We went on to characterize that binding site. We published the crystal structure with Mattia Skier, who's the sort of expert on NLRP3 structural biology. And there's a few, you know, unique features of this binding site that could, you know, translate it to potential advantages. The most important one is that our binding site is available when the NLRP3 is both, you know, active and inactive. And in contrast, the other binding site that everybody else binds into is only available in the inactive state, right? So that could translate into faster onset of efficacy as well as deeper efficacy. And we have seen so far in our phase one data set that we released back in April, you know, best in class reductions in IL-1 beta and the other inflammatory biomarkers that you look at to look at, you know, target induction here.

Seamus Fernandez Analyst — Guggenheim

Great. In terms of what has been shown so far, maybe we can kind of jump straight to the magnitude of effect on CRP, IL-6, IL-1 beta, as well as the safety and tolerability that you've seen so far.

Yeah, for sure. So we released a data setback in April, which included healthy volunteers, SADMAD, but we also looked in a couple of obese cohorts as well, so people with obesity and elevated inflammation at baseline. And that's because with this class, you can see such a rapid reduction of inflammatory biomarkers, like you can see it in a week. And what we demonstrated is a few things. So as I mentioned, best-in-class IL-1-beta reduction, so up to 98% IL-1-beta reduction, depending on the dose, which is, you know, to my knowledge, the highest that's been shown. Best-in-class CRP reductions as well. This is, you know, an inflammatory biomarker in a number of diseases, 86%. And similarly for the other biomarkers that people look at here, Vibratingin, etc. So potential best-in-class profile, and all very well tolerated to date, really not different from placebo in the phase one data so far.

Seamus Fernandez Analyst — Guggenheim

Great. Quell-CV, so we're on the cusp of, you know, data. So can you maybe just describe the study, you know, how are you thinking about dose response and the effect size?

Yeah, so QL-CV was, you know, originally inspired by the Ventix study, where they looked at an obese-inflamed cohort for three months and saw some really profound biomarker reductions. And was also, you know, the original thinking was to inform cardiovascular disease. So that's all shifted in the wake of Zeus, and we can speak to that. But QL-CV is still a really important study for us. And as I mentioned, these are people who at baseline are obese, have high inflammation, and so these individuals are at a risk of a whole bunch of different diseases, Whether it's MASH or diabetes or cardiovascular, and they're taking our drug at three different dose levels, 30, 60, 90, once a day for a three-month period. And we're looking at a very rich set of metabolic and inflammatory biomarkers, including, like, the canonical NLRP3 pathway ones, but more broad as well. We're also looking at MRI to look at liver inflammation, dexcess. We're going to learn a ton from this study in terms of the potential future application areas of the drug, in terms of the long-term safety, and also in terms of that dose that we will carry forward, right? Because right now it's an open question. Part of the reason we're doing dose raging here is that, you know, we're definitely maxing everything out at 90 milligrams once a day. That should give us the complete NIL-1 beta inhibition, but 60 might be just as good. So we'll know the answer coming out of the study.

Seamus Fernandez Analyst — Guggenheim

Got it. Okay, great. And then just in terms of some of the dynamics in the market today, there's a lot of data to suggest the relevance of IL-1 beta. Unfortunately, IL-6 has kind of hit a pretty hard stumble with the Zeus results. Maybe you can just help us understand the interpretation of Zeus, how you've looked at that data set, and then what it teaches us. But also what it doesn't teach us.

Yeah, for sure. Now, Zeus was, of course, was a big setback for the field, a big surprise back in July. And we just heard the deeper, you know, look at that from Paul Rydker at AHA just on Saturday and on Sunday. So overall, again, this is IL-6. So this is like very downstream relative to NLRP3. And it failed to show an effect in a cardiovascular outcome study that, you know, the hazard ratio was close to one. And this is in the context, too. The reason why they looked at this in the first place was because they saw a significant difference with IL-1 beta, right? So IL-1 beta is a different target, not affected by IL-6, but that is directly downstream of NLRP3, and we can speak to that in a minute. But in terms of IL-6 itself, you know, coming out of that study, the two potential possibilities are, you know, either it's the wrong population. So the famous Canto study where they showed that IL-1 beta inhibition had a really nice effect on meso outcomes, up to 25% as a function of CRP. That was in a healthier population relative to Zeus. So a number of people in the Zeus study had quite low GFRs. They may have had events that were unrelated to inflammation, right? But the other possibility, of course, is that it was the wrong target. You know, like IL-6 is very downstream. Upstream, you know, it produces CRP. It's certainly upstream of CRP, but maybe not of much else. So I think, you know, in the wake of Zeus, you know, and Paul Rydker spoke to this, and Novo was very explicit about this as well, like they are looking to upstream targets like NLRP3, where you're definitely going to get that IL-1 beta suppression, which previously has worked, and, you know, and where it's also more related to the data you see with colchicine, which is also, you know, an upstream drug that works.

Seamus Fernandez Analyst — Guggenheim

Yeah. And clearly, the industry hasn't backed off of NLRP3 as a key target, not just for cardiovascular disease, but for other areas as well. So can you walk us through sort of some of the other opportunities that you see, and obviously one being the retinal disorders as well?

Yeah, for sure. So I think there's been a lot of focus on the CV space given the Zeus trial, but it's underappreciated really how rich this biology is, right? Like there's a number of disease indications where an IL-1 or an IL-6 drug is either approved or moves the approvable endpoint, and we sit upstream of that, right, where we have the opportunity to hit multiple inflammatory cytokines at once as well as, you know, pyreptosis. So one, you know, the other indication that we're really excited about where we're running a big phase two now is in diabetic macular edema, and this is really part of our strategy about, you know, retinal inflammation in general. I mentioned that we built our drug to be brain penetrant. It has the best brain penetrance shown so far in humans, the KPU-CSF of 0.7. Our drug also gets really well into retina, so we're excited to take it to some of these inflammatory diseases. And that might, you know, be a unique feature of our drug. We'll see if the other drugs get there or not. But there are a number of different diseases driven by retinal inflammation, like geographic atrophy, like diabetic macular edema. And we're starting with DME for a couple of reasons. One is that the IL-6 injections have moved the approval endpoint. Kodiak and Roche have very nice efficacy data here. The PIs, you know, physicians are starting to get pretty excited about these drugs in combination with VEGF to really improve vision in this patient population where there's a ton of unmet need. And what's appealing about our drug, of course, is that instead of an injection into one or both of your eyes, it's a pill you can take once a day, right, that hits IL-6, but also pyroptosis and other inflammatory cytokines too. And what I really like about DME as well is that it's happening in the context of diabetes, right? So that your body isn't just a convenient way to deliver the drug to your eye. There's potential systemic benefits as well that we're excited about. Importantly, too, one last point is that this really unlocks a patient segment which is not treated today. So physicians usually wait until the disease is quite severe because the intervention is severe. It's an injection into your eye, right? So there are 30% to 40% of patients where it's more watch and wait, where a well-tolerated oral would be very appealing.

Seamus Fernandez Analyst — Guggenheim

Okay. And in terms of the design of the study, the patients recruited, you know, What exactly are we going to be looking for in the DME study?

Yeah, so this is 180 patients overall. So we have power to show a four-letter improvement, which would be very clinically meaningful, either as a monotherapy or on top of VEGF. So we have three different groups right now. So we have our drug by itself, BG-1N-1O2 by itself, VEGF by itself. This is the standard of care as well as the combination. And, you know, the combination is where people are looking at IL-6, right, because it's another injection, but we also are excited about the monotherapy because for a couple of reasons, right, it should be able to do more than IL-6, but also it should be able to access that patient population where the VEGFs are not going today.

Seamus Fernandez Analyst — Guggenheim

And maybe just help bridge folks from, you know, sort of the Kodiak and Roche data to how NLRP3 could be relevant just more mechanistically.

Yeah, so Roche and Kodiak are just pure, basically, IL-6 drugs, right? Which is one of the inflammatory cytokines where you see a really potent reduction with NLRP3. So we should be able to capture that effect. But pyroptosis, you know, is also very much implicated in the pathology here of DME. And that's like a sort of a separate mechanism, like IL-18, etc., by which NLRP3 should be able to have efficacy as well.

Seamus Fernandez Analyst — Guggenheim

Okay, super interesting. And just the timing of those data?

Yeah, so that'll be in the back half of next year. Yeah, and yeah, you know, one important point, too, like when we originally conceived of this study, it was originally going to be a biomarker study, but we decided to power it up, make it a true efficacy study, and because we're looking at the approvable endpoint, we could potentially go into a pivotal study after this reads out next year. So we're really excited about this data. And as we touched on at the very beginning, too, right, this is unlocking not only DME, but also retinal inflammation more broadly. Like there's a lot of investor interest in MEZI, there's an orphan condition, but also geographic atrophy. The rationale is very compelling. There are really no therapies that work in terms of improving vision, and we're really excited to take the mechanism there as well.

Seamus Fernandez Analyst — Guggenheim

Great. And in terms of, you know, what are the next steps after QL-CV reads out? So is that kind of watch and wait? Let's see what happens with Artemis, or are there, you know, sort of subpopulations in the CV setting that could be potentially interesting?

Yeah, great question. So we're certainly not going to go right into a MACE trial. That's, you know, on pause for sure. That said, if Artemis were to read positive, we would be able to follow pretty quickly, right? Right, so Artemis is the one sort of Novo trial still standing with IL-6, where the patient population is closer to the post-MI1, where they saw a nice effect in Cantos, right? So like the less sick patient population. It's still not quite the same study design, right? And there's still that question about, is it the right target? But contingent on positive data there, we would definitely, you know, reconsider going back into sort of full MACE. The other interesting thing we're watching for is to see what Lilly does with the Ventex drug, right? Like, that'll be, maybe we'll get some hints in the next month or so. We'll see. But from our perspective, as I mentioned, right, there's a whole host of indications where these downstream drugs are approved. These injectable downstream drugs are approved. So we will be selecting another peripheral indication, or we'll talk about it when we have, you know, all our milestones lined up, et cetera. But we are going to be developing it for a peripheral indication where, you know, we can look at the approval endpoint in our next trial, Like, as a small biotech without the $600 million of May spent.

Seamus Fernandez Analyst — Guggenheim

Yeah, and... In terms of other competitors and where other competitors are kind of taking their NLRP3s, what areas do you kind of view as potentially interesting?

Yeah, I mean, you know, there's a lot to choose from here, right? Like IL-1 and IL-6 biology, again, are like approved sort of in many different indications. So our focus is really on a few things. One is where we're unique, and that's really where the eye makes sense for us, right? We don't even know that these other drugs get into the eye in a way to be therapeutic, so that's very unique for us, the eye and the brain. But it's also important for us to select indications where we can go it alone as a small company, right? And there's a few to choose from there. I mean, you know, there's companies looking at HS, at gout, RP, you know, there's a whole sort of suite of promising indications, and we'll, you know, communicate more once we're ready.

Seamus Fernandez Analyst — Guggenheim

Let's talk about APJ. Okay. You know, maybe just remind us the original program and, you know, what you learned from that program in particular. And then as you advance your new program, what are you most focused on?

Yeah, for sure. So as a reminder for everybody, our original program was a Zaloprag. This is a drug that we in-licensed from Amgen after phase one, and it targets the APJ receptor. So it mimics the effects of a peptide called apolin, which is a sort of natural circulating peptide that has been described in literature as an exercise. You know, it's responsive to exercise, seems to, you know, mediate some of the positive benefits of exercise. If you go for a run or a bike ride, your apolone will spike. And we showed previously that with the Amgen drug, with other drugs in this pathway, that you could do a couple of things. You could preserve muscle from muscle loss, and you could also increase weight loss in combination with an encretin, right? And so we were in a phase two study with Lilly a couple years ago when their drug, the Amgen drug, ran into, there were some liver issues. There were some liver enzyme elevations, which caused us to halt the program. It just wasn't an okay profile for that population, like healthy or obese. We went back to the drawing board, and the universal feedback we got from all the experts we spoke to that it was structure-related toxicity. So our design goal from the beginning was to create totally different chemistry, completely unrelated to the Amgen chemistry, which is what we've done. So we're really excited to, you know, we'll roll out the data set soon, but the plan here is really very similar. And one other thing I'll mention is that we showed in the clinic as well that with Amgen's APJ agonist, we could preserve muscle. So we did a small human experiment where you have these older people in a bedrest intervention, right? So you have older people, and the intervention is they're sitting in bed for 10 days. They're not moving the whole lower half of their body. And this very reproducibly gives you a reduction in the amount of muscle in your thigh, which you can measure a number of ways, and more fat infiltration into the thigh. And we showed that we protected significantly from that with our drug. So we're really excited to get back in the clinic with APJ. And the potential here is really the same, right? And if anything, it's even more exciting than it was a couple years ago, Because the big opportunity was always, this is something you could combine with an oral incretin to increase weight loss and also improve body composition, retain more lean muscle. And now that we've seen some of these drugs get approved, like Orpho, they're really not competitive with the injectables in terms of the amount of weight loss. So there's a really big value proposition, I think, to sort of having a combo pill that increases weight loss. And, of course, there's even more and more of a focus on having that weight loss be healthy, which is another advantage we have here as well. So that'll be following the same sort of path there.

Seamus Fernandez Analyst — Guggenheim

Got it. So Still on the obesity path, I guess one question is, as we work and speak with a lot of obesity companies, the feedback, especially from patients and in the work that we do, is maintenance is probably the number one area that, you know, companies are kind of trying to crack the code. If they could enter maintenance late, they would feel like they're maybe not competing with Lilly and Novo. What is the, you know, is that a profile? Is that something that can be studied relatively early from your perspective?

So I think the science is there, definitely, right? Like, first of all, I'll point out that it's not really competing with Lilly or Novo because it's an add-on. You know, it's something you would take with it, right, for, like, the weight induction regimen. But to your point, in terms of maintenance, we've shown, like preclinically at least, that if you give Apolin as a monotherapy, that reduces the amount of weight that you gain on a high-fat diet if you're a mouse. And of the weight, you gain a higher proportion as muscle. So it's also healthier weight gain. So it does have a lot of potential there. Those are bigger trials, you know, because the effects are smaller. It's certainly an interesting area where the biology makes sense for us as well.

Seamus Fernandez Analyst — Guggenheim

Got it. And maybe just to wrap up, you know, in terms of when, you know, from IND to data, I think you have a pretty good sense of, you know, what's possible from your Zaloprag work. When would we anticipate post-IND, like, how quickly can we get to some answers at least?

Yeah, no, that's a great question. We don't have our formal guidance yet, because I don't really like to do that until we've, you know, officially submitted our IND. But we're on track to do that by end of year. And then, you know, a sad mad takes as long as a sad mad takes. And something like a bedrest, you know, proof of concept trial, where you just put people in bed for a couple of weeks and look at muscle, which is a great sort of PD trial here that can also be pretty, pretty quick.

Seamus Fernandez Analyst — Guggenheim

And is there a potential opportunity for this novel asset? Um, just in the way that it finds to apelin and, and, you know, how differentiated is it from a zeloprag on all of the key, uh, positives that a zeloprag could take on the table?

Yeah, yeah, basically. Um, so, well, I guess, I guess we haven't sort of publicly said how potent it is, stuff like that. So I can't, I can't sort of compare it on those dimensions. Uh, it's just, you know, I actually, I think we have, yeah, so it is highly potent. Okay. It's more than tenfold more potent than a zeloprag.

Seamus Fernandez Analyst — Guggenheim

Okay.

And very different chemistry, as I mentioned.

Seamus Fernandez Analyst — Guggenheim

Yeah. So feel good about like how it's positioned versus a zeloprag. Definitely. To deliver similar type results.

Yeah. We also, I mean, part of the design goal too, back with a zeloprag, we had to have daily doses of like 300 plus megs a day, right? So part of our design goal was also to get that a lot lower.

Seamus Fernandez Analyst — Guggenheim

Okay. And just to wrap up, BioAge's cash position And just the cash runway?

Yeah, at our last update, we were just north of 350 million, which gives us runway through 29 with all the programs we've discussed, as well as with, you know, another indication for NLRP3.

Seamus Fernandez Analyst — Guggenheim

Great. Super exciting time. Thank you so much for joining us. And we'll look forward to, I guess, QL-CV very soon. Coming soon. And, you know, obviously DME is super exciting. Thank you. Thanks so much, Kristen.

Analyst Q&A · 1 question
Full-screen source Call document